<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519814</url>
  </required_header>
  <id_info>
    <org_study_id>T1703PM</org_study_id>
    <nct_id>NCT04519814</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of VISULAS Green Selective Laser Trabeculoplasty (SLT)</brief_title>
  <official_title>A Prospective, Multicenter Clinical Investigation to Evaluate Safety and Effectiveness of VISULAS Green Selective Laser Trabeculoplasty (SLT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional, open, prospective, multi-center pre-market clinical investigation&#xD;
      according to §§20-23a Medizinproduktegesetz (MPG, medical devices act), in which a total of&#xD;
      40 eyes of 40 consecutive patients at up to five (5) clinical sites will be enrolled, treated&#xD;
      with the VISULAS green with option CSLT, and followed for a three months period.&#xD;
&#xD;
      The primary objective of this clinical investigation is to evaluate safety and effectiveness&#xD;
      of SLT with the VISULAS green laser with option CSLT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean absolute change in intraocular pressure (IOP) compared to baseline at month 1</measure>
    <time_frame>one (1) month</time_frame>
    <description>The endpoint is the mean change in IOP (Absolute value, mmHg) of the study cohort compared to baseline at month 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean relative change in intraocular pressure (IOP) compared to baseline at month 1</measure>
    <time_frame>one (1) month</time_frame>
    <description>The endpoint is the mean change in IOP (relative value, %) of the study cohort compared to baseline at month 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean absolute change in intraocular pressure (IOP) compared to baseline at month 3</measure>
    <time_frame>three (3) months</time_frame>
    <description>The endpoint is the mean change in IOP (Absolute value, mmHg) of the study cohort compared to baseline at month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean relative change in intraocular pressure (IOP) compared to baseline at month 3</measure>
    <time_frame>three (3) months</time_frame>
    <description>The endpoint is the mean change in IOP (relative value, %) of the study cohort compared to baseline at month 3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>rate of patients achieving &gt;0 to &lt;10% IOP reduction from baseline</measure>
    <time_frame>three (3) month</time_frame>
    <description>The following exploratory endpoint will be determined additionally:&#xD;
- rate of patients achieving &gt;0 to &lt;10% IOP reduction from baseline at 1 and 3 months</description>
  </other_outcome>
  <other_outcome>
    <measure>rate of patients achieving 10% to &lt;20% IOP reduction from baseline</measure>
    <time_frame>three (3) month</time_frame>
    <description>The following exploratory endpoint will be determined additionally:&#xD;
- rate of patients achieving 10% to &lt;20% IOP reduction from baseline at 1 and 3 months</description>
  </other_outcome>
  <other_outcome>
    <measure>rate of patients achieving ≥20% IOP reduction from baseline</measure>
    <time_frame>three (3) month</time_frame>
    <description>The following exploratory endpoints will be determined additionally:&#xD;
- rate of patients achieving ≥20% IOP reduction from baseline at 1 and 3 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-operative intraocular pressure (IOP) in mmHg</measure>
    <time_frame>one (1) day</time_frame>
    <description>Outcome Parameters Safety: Post-operative intraocular pressure (IOP) in mmHg: 1h, 1d</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of intraoperative Adverse Device Effects</measure>
    <time_frame>one (1) day</time_frame>
    <description>Outcome Parameters Safety: Rate of intraoperative Adverse Device Effects</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Adverse Device Effects and Device Deficiencies</measure>
    <time_frame>three (3) month</time_frame>
    <description>Outcome Parameters Safety: Rate of Adverse Device Effects and Device Deficiencies over the entire course of the investigation</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Adverse Events and Severe Adverse Events</measure>
    <time_frame>three (3) month</time_frame>
    <description>Outcome Parameters Safety: Rate of Adverse Events and Severe Adverse Events over the entire course of the clinical investigation</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>all eligible patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 40 eyes in 40 consecutive patients, 22 years of age or older, with primary open-angle glaucoma (HPG + NPG), who did not reach target pressure, agree to participate in the study, and will be able to complete clinical follow-up and evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>selective laser trabeculoplasty (SLT)</intervention_name>
    <description>Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.</description>
    <arm_group_label>all eligible patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females at least 22 years of age or older, primary open-angle glaucoma (HPG&#xD;
             + NPG), who did not reach target pressure .&#xD;
&#xD;
          -  IOP with or without medications ≥17 mmHg in the study eye&#xD;
&#xD;
          -  Chamber angle Shaffer 3 and 4&#xD;
&#xD;
          -  Patients must be legally competent and able to give consent and must have read,&#xD;
             understood and signed patient information leaflet and consent to undergo SLT in one&#xD;
             eye&#xD;
&#xD;
          -  Patients are willing and able to return for follow-up examinations&#xD;
&#xD;
          -  In the opinion of the investigator, the patient will be compliant and have a high&#xD;
             probability of completing the clinical investigation and all required procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Corneal disease or pathology in a way that distortion of laser light in the study eye&#xD;
             can be expected or that precludes stabilization of the cornea by the contact glass,&#xD;
             visibility of the trabecular meshwork or transmission of laser wavelength&#xD;
&#xD;
          -  Strong clouding of the anterior ocular media (e.g. the lens due to dense cataract) and&#xD;
             the vitreous body (e.g. due to strong vitreous hemorrhage) in either eye&#xD;
&#xD;
          -  Deep orbits and/or narrow palpebral fissures&#xD;
&#xD;
          -  Corneal or conjunctival abnormality precluding contact lens adaptation in either eye&#xD;
&#xD;
          -  History of Amblyopia in either eye&#xD;
&#xD;
          -  Any contraindications to SLT in study eye.&#xD;
&#xD;
          -  Any kind of planned ocular surgeries during the next 3 months (for example, cataract&#xD;
             surgery) in either eye&#xD;
&#xD;
          -  Previous intraocular or corneal surgery of any kind (except cataract surgery longer&#xD;
             than three months prior to the clinical investigation), including surgical glaucoma&#xD;
             intervention in study eye before the clinical investigation.&#xD;
&#xD;
          -  Signs of Fuchs' Dystrophy (e.g. corneal endothelial guttata) in either eye&#xD;
&#xD;
          -  Active or history of Uveitis in either eye&#xD;
&#xD;
          -  Congenital glaucoma in either eye&#xD;
&#xD;
          -  Diabetic retinopathy or branch retinal vein occlusion with the risk to develop&#xD;
             neovascularizations in either eye&#xD;
&#xD;
          -  Heavily pigmented trabecular meshwork due to pseudoexfoliation syndrome or pigment&#xD;
             dispersion glaucoma in either eye&#xD;
&#xD;
          -  Degenerative disorders of the central nervous system if it prevents proper compliance&#xD;
             or the ability to undergo the tests in the clinical investigation (e.g. Parkinson&#xD;
             Disease, Alzheimer Disease, or other forms of dementia)&#xD;
&#xD;
          -  History of or has a current, clinically significant major psychiatric disorder (e.g.,&#xD;
             major depressive disorder, psychosis, schizophrenia)&#xD;
&#xD;
          -  Patients who are pregnant, lactating, or of child-bearing potential and not practicing&#xD;
             a medically approved method of birth control.&#xD;
&#xD;
          -  Enrollment in another drug or device study within the prior 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Senior Manager Clinical Affairs</last_name>
    <phone>+493641220</phone>
    <phone_ext>0</phone_ext>
    <email>info.meditec@zeiss.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Augenheilkunde, TU Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Pillunat, Dr. med.</last_name>
      <phone>+49(0)351 458-2251</phone>
    </contact>
    <investigator>
      <last_name>Karin Pillunat, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augenarztpraxis am Dreiecksplatz, Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Koinzer, PD Dr. med.</last_name>
      <phone>+49 431 515 66</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Augenheilkunde, UK Schleswig Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Ehlken, Dr. med.</last_name>
      <phone>+49 431 500 24202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augentagesklinik Rheine</name>
      <address>
        <city>Rheine</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Kretz, Dr. med.</last_name>
      <phone>+49 5971 807 09 60</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

